Horrell Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

Horrell Capital Management’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.4K	Buy	+65	New	+$11.2K	0.01%	144

Other funds holding IBB

Generali Investments CEE Prague, Czech Republic $2.11B AUM 25.53% 1-Year Est. Return

Folger Nolan Fleming Douglas Capital Management Washington, District of Columbia $1.22B AUM 34.81% 1-Year Est. Return

Apella Capital West Hartford, Connecticut $7.08B AUM 17.38% 1-Year Est. Return

Reyes Financial Architecture San Diego, California $179M AUM 31.17% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return

Neville Rodie & Shaw New York $1.55B AUM 46.95% 1-Year Est. Return

McCollum Christoferson Group Amherst, New York $341M AUM 15.01% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Southern Capital Advisors Jackson, Tennessee $239M AUM 22.42% 1-Year Est. Return

Horrell Capital Management's IBB Position: Q2 2026 in Review

Horrell Capital Management opened a new position in iShares Biotechnology ETF (IBB) in Q2 2026: 65 shares worth $12.4K. The stake represents 0.01% of the portfolio and ranks #144 among its holdings.

158 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

Horrell Capital Management held 65 shares of iShares Biotechnology ETF worth $12.4K as of Q2 2026.
iShares Biotechnology ETF was a new Horrell Capital Management position in Q2 2026.
iShares Biotechnology ETF made up 0.01% of Horrell Capital Management's portfolio in Q2 2026, its #144 holding.
158 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Horrell Capital Management's 13F filing for Q2 2026, filed 16 Jul 2026.